INTRODUCTION 1
There are an estimated 1 million cases of childhood tuberculosis (TB) each year 2 and in 2015, 210,000 children died of TB 5 . Children with TB are difficult to 3 diagnose and treat and are at risk of severe disease 6 . The need for improved 4 strategies to control childhood TB has led to studies to identify risk factors for 5 TB disease in children. The longitudinal data collected during infant TB vaccine 6 efficacy trials in South Africa with the vaccines BCG and Modified Vaccinia 7 Virus Ankara expressing Antigen 85A (MVA85A) 1, 7 have enabled the 8 identification of correlates of TB disease risk in infants 3, 8 . Using samples 9 collected at enrolment from infants into the MVA85A efficacy trial in the Western 10 Cape Province of South Africa 1 , we reported that CD4+ T-cell activation in 4-6 11 month old infants and adolescents, measured as HLA-DR expression, was 12 associated with increased risk of TB disease over the following 3 years of life 8 . 13 The consequences of chronic T-cell activation are well-described in HIV and 14 include risk of acquisition of infection, risk of progression from infection to 15 disease, increased risk of non-communicable disease and aging [10] [11] [12] [13] [14] . 16 Recognition that T-cell activation is a feature of HIV immunopathogenesis has 17 guided the development of new interventions for management of HIV 15 . 18
Improved understanding of the causes and impact of T-cell activation on TB 19 disease risk, could transform future approaches to protect against TB. Such 20 approaches could include the use of vaccines, antibiotics or antivirals to reduce 21 the burden of chronic microbial drivers of T cell activation. 22 
23
Sustained T-cell activation and dysfunction of antigen specific T-cells can result 24 from chronic exposure to antigen from persistent viral or bacterial infections 9 . Infants who were enrolled in an efficacy trial of the candidate TB vaccine MVA85A were included in this study 1 . Infants were randomized at 16-24 weeks of age to receive a single intradermal dose of MVA85A or placebo (Candin™, a candida skin test antigen) 1 .. Boxes indicate the number of case infant (red) or control infant (grey) samples available for combined Day 0 (D0) and Day 28 (D28) analysis. Analysis was restricted to infants where a frozen PBMC sample was available, live cells in PBMC were >50% (or PHA IFN-γ ELISPOT >=1000 SFC/million) and to infants where a sample was available for analysis from both the D0 and D28 time points. Control infants were excluded if the corresponding matched case was not in the analysis. We analyzed CMV and EBV-specific IFN-γ ELISpot responses for evidence of 1 an association between viral infection and T-cell activation in our infant cohort. Figure 2C ). CCL8, CXCL10 and IFIT3 had the greatest fold 3 increase in expression in EBV+ infants indicating strong induction of a Type I/II 4 IFN response, although we did not see a correlation between EBV ELISpot 5 response and T cell activation in this study (Supp Table 1 ). 6
The impact of CMV on the blood transcriptome was smaller, with only 14 genes 7 differentially expressed between CMV positive and negative infants (ELISpot 8 >17 SFC/million), although there were 103 differentially expressed transcripts 9 between CMV strongly positive (ELISpot >100 SFC/million) and negative 10 infants (Figure 2D and Supp Tables 2A and B). Differentially expressed  11   transcripts included HLA-DRB1, ZNF683, LAG3 and KLRC2 (NKG2C). ZNF683  12 is an important paralog of PRDM1 and together with CCL5 has been shown to 13 be highly induced in human CMV-specific CD8+ T-cells when compared to 14 naïve CD8+ T-cells 22 . LAG3 is expressed on activated CD8+ and CD4+ T-cells 15 and LAG3+CD8+ T-cells are found in CMV infection 22, 23 . NKG2C+ natural killer 16 (NK) cells are expanded in response to CMV infection although CMV infection 17 can also induce the expression of NKG2C on CD8+ T-cells [24] [25] [26] . . CMV+ infants are at increased risk of developing TB disease A) We saw a higher proportion of case (red) infants among CMV+ (n = 18/32) when compared to CMV-infants (n = 35/140). B) There was no significant enrichment for cases among EBV positive infants (n = 3/7 compared to n = 46/162) although Infants positive for either CMV or EBV (C) were at increased risk D) CMV+ infants (red) develop TB disease earlier in follow-up when compared to CMV-infants (blue) and E) Infants positive for either CMV or EBV develop TB disease earlier than CMV/EBV-infants.
A D E C B
A CMV specific IFN-γ response measured at 4-6 months of age, up to 3 years 1 before disease is detected, was a risk factor for the development of TB disease 2 in South African infants and this risk was greatest during the first 10 months of 3 follow-up. 4 5
Transcriptional evidence of activated T-cells, Type I IFN responses and 6

NK cells in infants up to 3 years prior to detection of TB 7
Because CMV ELISpot positive infants were at greater risk of disease, we 8 stratified transcriptome data by CMV status to identify transcripts able to 9 classify case and control infants. When CMV+ and CMV-infants were analyzed 10 together, 16 genes were significantly differentially expressed between cases 11 and controls ( Figure 4A and Supp Table 3 ). LAG3 and VCAM1, known markers 12 of T-cell activation 23, 27, 28 , had the greatest fold increase in expression in case 13 infants. To test our ability to classify infants into cases or controls we split 14 samples randomly into a 70% training set and 30% test set and trained an 15 artificial neural network (Additional Figure 3A) . The process was repeated fifty 16 times with random splits into training and test set (bootstrapping) and AUROC 17 and accuracy were recorded to assess predictive stability (Additional Figure 4) . 18 When all infants were included in the analysis we could classify infants into Enriched modules for differential expression in case and control infants amongst all, CMV+ and CMV-infants. Each row contains one module with the number of genes indicated. Each significantly enriched module at a p-value < 0.05 is shown as a pie chart. The size of the pie corresponds to the AUROC in the cerno test, and intensity of the colour corresponds to the enrichment q-value. The red and blue colour indicates the amount of significant up and down regulated genes respectively, grey color indicates the remaining not significant genes within the category. The interaction term evaluates the statistical difference between changes in CMV+ and CMV-infants. E) AUROC of the classification performance of the artificial neural network model which was trained using approximately 70% of the data and risk of TB was predicted on the withheld 30% of the data (Additional Figure 3 A). The process was repeated fifty times with random splits into training and test set (bootstrapping) and the AUROC was recorded for each round for E) CMV+ and F) CMV-infants respectively.
20
Additional Figure 3 . Classification strategy and model comparison A) Overview of the classification strategy for TB risk prediction. An artificial neural network model was trained using approximately 70% of the data and TB risk was predicted on the withheld 30% of the data. Only significantly differentially expressed genes were used as features for classification for each set of infants and model parameters were tuned using leave one infant out cross validation. The process was repeated fifty times with random splits into training and test set (bootstrapping) and AUROC and balanced accuracy were recorded for each round. B) Classification performance comparison of seven models applied to the datasets. Table 4 ). IL32 enhances maturation of monocytes to 5 macrophages and has been shown to be important for protection against 6
Mycobacterium tuberculosis (M.tb) 29 . In our cellular analysis we observed 7 decreased frequencies of CD3-CD8-CD4-(triple negative) CD16-and CD16+ 8 natural killer cells in infants who develop TB disease in the next 3 years when 9 compared to CMV+ infants who do not develop disease (Additional Figure 6B) . 10
In CMV-case infants, elevated expression of T-cell activation markers, 11 including LAG3 and VCAM1, markers of a type I/II IFN response including 12 IFIT3, and enhanced expression of a broad range of both activated and 13 inhibitory KIR receptors including KIR2DL1, KIR2DL3, KIR2DL4, KIR2DL5A, 14 KIR2DS3, KIR2DS5, KIR3DL1 and KIR3DL3 were observed ( Figure 4C and 15 Supp Table 5 ). Modular pathway analysis showed enrichment for NK and KIR 16 cluster genes and a type I/II IFN antiviral immune response in CMV-case 17 infants when compared to controls ( Figure 4D ). However, we saw no evidence 18 of increased NK cell frequency in infants who develop TB disease in our cellular 19 analysis (Additional Figure 6B) . 20 TB risk associated transcripts and immune pathways were different among 21
CMV+ and CMV-infants, as highlighted by a modular pathway analysis which 22
uses an interaction term to compare pathways associated with TB risk among 23 CMV+ and CMV-infants ( Figure 4D and Supp Table 6 ). 24 To validate the classifier signatures, we used raw data from an independent 1 cohort of 10-week-old South African infants vaccinated with BCG at birth and 2 unknown CMV status (GEO gene set GSE20716, Fletcher et. al.
3 ) Infants were 3 enrolled into an efficacy trial of intradermal or percutaneous delivery of 4 Japanese BCG at birth 7 . A nested correlates of risk study was performed using 5 blood from 10-week-old healthy infants who developed TB disease within the 6 next two years 3, 30 . We sought to remove technical differences between the two 7 array data sets to enable validation of classifier signatures (Additional Figure  8 7A), however, we could not fully normalize expression between the two data 9 sets, most likely due to the age difference between infants in the two cohorts 10 (2-3 months in GSE20716 and 4-6 months in the MVA85A efficacy trial) 11 (Additional Figure 7B ). Despite these cohort differences and the loss of more 12 than half of the genes in our signature due to microarray platform differences, 13
we were able to predict risk of TB using our CMV-classifier with an accuracy 14 of 63.9% and an AUROC of 0.71 (95% CI 0.63-0.79, Additional Figure 7C ). (GEO  gene set GSE20716 3 ) were used as a validation cohort for the classifier signatures from CMV+ and CMV-infants. 20589 Probes from 182 samples were mapped from Illumina HumanRef-seq 8 arrays to Gencode v.23 and 8 outlier samples were excluded A) The effects of time point (4 or 12 hours) and BCG Stimulation (stimulated or unstimulated) were removed and 9195 probes identified as overlapping between the two studies. B) We were only partially able to remove differences in gene expression due to study of origin. The differences observed in PC2 are driven by age, which was non-overlapping in the two studies, 2-3 months in GSE20716 and 4-6 months in the MVA85A efficacy trial.C) Using 55 genes differentially expressed between infants with very high or low CMV titres at an FDR of 5%, 5 infants were identified to have two or more CMV positive samples. D) The charts represents one dot per sample and red colour indicates samples classified as CMV+. The TB Risk dot plot shows samples with correctly predicted Case (TP) and Control (TN) status as well as samples with wrong Case (FP) and Control (FN) labels. E). Excluding all five suspected CMV+ infants we were able to improve risk of TB prediction accuracyon GSE20716 3 slightly, with balanced accuracy of 65.6%.
Finally, we looked for enrichment of transcripts from the 16-peripheral blood 1 gene correlate of risk (CoR) signature associated with progression to TB 2 disease in M.tb infected adolescents 2 among our CMV+ and CMV-infants. This 3 adolescent CoR signature was significantly enriched among case infants when 4 compared to controls and the enrichment was strongest amongst CMV-infants 5 (Additional Figure 8A) . However, the adolescent CoR signature was not able 6 to accurately classify infants into cases and controls (Additional Figure 8B) . 7
Including the CoR score in our infant network analysis we show that the CoR 8 score correlates with the frequency of inflammatory monocytes and with our 9 CMV-classifier signature (Additional Figure 8C Figure 8D) . 16 17 Additional Figure 8 . Enrichment of TB predictive Correlate of TB Risk score (CoR) from adolescents among CMV-case infants when compared to controls, but no accuracy for prediction of TB in infants. Using a locked-down Illumina model published by Zak et al 2 for prediction of TB progression, a blinded CoR score was derived for each infant. A) After unblinding, the CoR score was found to be significantly higher in case infants when compared to controls and the greatest difference in CoR score was between CMV-case and control infants B) However, despite enrichment in case infants, the CoR score was unable to accurately classify either CMV+ or CMV-infants as cases or controls. C) The CoR score correlates with the frequency of inflammatory monocytes and the CMVinfant classifier signature. D) Network of positively correlating cell populations (spearman rho p-value <0.05) showing a cluster containing the adolescent CoR score with monocytes, EBV ELISpot and the infant CMV-classifier score. Node colour indicates community membership and red and black edges are drawn between and within communities respectively (see methods). Edge width indicates the correlation coefficient. are associated with increased risk of developing TB disease over the next 3 years of life. We also show that CMV+ infants acquire TB disease earlier than CMV-infants. These data complement our previous finding that CD4+ T-cell activation was associated with TB disease risk in infants and adolescents from a South African community with very high TB incidence 8 . Previous studies have reported that infection with CMV enhances the risk of HIV acquisition and disease progression, through expansion of activated CD8+ T-cells, depletion of naïve T-cells and T-cell senescence [11] [12] [13] [14] . More recently, CMV has been implicated in the aetiology of TB, supported by epidemiological associations between the two diseases [17] [18] [19] [20] [21] . In Gambian infants, CMV infection induced profound CD8+ T-cell differentiation and activation which persisted up to 2 years after infection 31, 32 . Consistent with this effect, we show that infants with a positive T-cell response to CMV peptides have a transcriptional signature associated with CMV specific CD8+ T-cells 22 . However, among CMV+ infants, T-cell activation markers were not differentially expressed between case and control infants.
In CMV+ infants, transcripts associated with NK cells had lower expression and NK cell frequency was lower in cases when compared to controls. A role for NK 34 cells in protection from TB disease has been demonstrated both in humans and animal models and it is possible than an impaired NK cell response is associated with TB disease risk among CMV+ infants [33] [34] [35] [36] [37] [38] [39] . CMV infection promotes the expansion of NK cells expressing the CD94/NKG2C activating receptor, and these cells are important for control of viral replication 40 . The CD94 and NKG2C transcripts KLRC1 and KLRC3 had among the greatest decreases in fold-change of expression and the highest predictive power in identifying cases among CMV+ infants. The NKG2C receptor is encoded by the KLRC2 gene, heterozygous and homozygous deletion of which is present in a significant proportion of individuals across different populations 41 . KLRC2 deletion is associated with reduced numbers of mature NK cells and increased susceptibility to HIV infection, certain autoimmune conditions and cancer [41] [42] [43] .
We hypothesize that increased susceptibility to TB in CMV+ infants may result from loss of control of CMV replication and/or impairment of NK cell function due to KLRC2 gene deletions in some individuals 17 .
Among CMV-infants, who went on to develop TB, we observed upregulation of transcripts associated with T-cell activation, including LAG3 23 which is induced during active TB in a non-human primate model 44 . We also found multiple transcripts and pathways that are typically altered during viral infection among CMV-infants. This may be due to underestimation of the prevalence of viral infection, as we used only IFN-g responsiveness to EBV and CMV CD8
epitopes as a measure of viral infection. Based on previous studies of viral prevalence in infants in Africa we would expect a CMV prevalence of 24-41% 45, 46 and EBV prevalence of 35% by 6 months of age 47, 48 . Detection of viral DNA would allow more accurate diagnosis of viral infection, however, this was 35 not possible due to the very limited samples collected from these infants.
Moreover, viruses other than those measured in this study (CMV, EBV) may be contributing to risk of TB disease among these infants. Expression of a broad range of both activating and inhibitory KIR receptor transcripts was elevated in CMV-case infants. Exposure to multiple viral infections drives high diversity of KIR expression and lowers the availability of naïve NK cells to respond to future infectious challenge, resulting in susceptibility to HIV 49, 50 . We were able to identify different classifier signatures among CMV+ and CMV-infants and were able to verify our CMV-signature in an independent cohort of infants 3 . In the independent cohort, infants were younger (2-3 months of age) and few infants were classified as CMV positive. CMV infection and viral replication is low at birth, peaks at 3-6 months of age and declines to plateau at 8-10 months of age 51 . At 4-6 months of age, infants recruited in to the MVA85A efficacy trial 1 were at the peak age of CMV viral replication in infancy. However, the CoR signature was not able to accurately classify case and control infants. In our study, the infants were not infected with M.tb, had no symptoms of TB disease and no known exposure to TB in the household during enrolment or when the blood samples were obtained. In addition, since incident TB disease was diagnosed months to years after blood sample collection it is unlikely that the elevated type I/II IFN associated transcriptomic signatures we observed are a result of sub-clinical TB disease. Although there was no evidence of BCG vaccine-induced disease in these infants we cannot rule out that persistent, sub-clinical, replication of BCG vaccine could be driving a type I/II IFN response in some infants.
All infants in this study received BCG at birth and the T cell response to BCG peaks at 2-3 months of age 58 . Viral infections during the development of the BCG-specific immune response may impair the development of protective immunity, as has been suggested by studies in Malawi 59 . In the Gambia, exposure to HIV in utero and being born in the wet season, associated with increased respiratory and diarrheal disease, have been shown to impact the BCG antigen specific T-cell response following vaccination 31, 60 . We observed an inverse correlation between CD4+ and CD8+ T-cell activation and antigen specific T-cell responses following immunization with MVA85A, suggesting that T-cell activation may be associated with decreased vaccine boosting in infants.
This confirms previous observations where increased immune activation 37 associated with lower immune responses to MVA85A in both infants and adults 61, 62 It could also explain why immune responses to MVA85A were lower when administered within a week of vaccination with DTwP-Hib and hepatitis B in the Expanded Programme on Immunization (EPI) schedule 63 .
Childhood TB is difficult to diagnose and treat and improved strategies are needed to control TB in children 5 . We found that CMV infection was associated with increased risk of developing TB disease in infants and that distinct immune pathways were associated with TB disease risk in CMV+ and CMV-infants. We suggest that viral infection can increase the risk of progression to TB disease and may compromise the immune response to TB vaccines given in infancy.
Strategies which include the use of vaccines or antivirals to reduce chronic viral infection in infancy could enhance TB vaccine efficacy, reduce TB risk and help to reduce the global burden of childhood TB.
METHODS
Case-control design
BCG-vaccinated infants who were enrolled in an efficacy trial of the candidate TB vaccine MVA85A were included in this study, ClinicalTrials.gov number NCT00953927 1 (Figure 1 ). This trial was approved by the University of Cape Transcriptomic analysis was performed using PBMC from infants who were included in our previously described case-control study 8 . Briefly, infants who met the primary case definition for TB disease were included as cases and for each case, three infants were randomly selected from a pool of controls ( Figure   1 ). Infants were included in the control pool if they did not demonstrate M.tb infection as defined by a positive QuantiFERON TB Gold In-tube test (Cellestis, Australia); had not received TB treatment and had not received isozianid preventive therapy during study follow-up. Matching was based on gender, ethnic group, CDC weight-for-age percentile (± 10 points), and time on study (± 9 months).
Infant PBMC samples collected from two time points Day 0 (D0) and Day 28 (D28) were combined for testing of both cellular parameters and transcriptional signatures associated with risk of TB disease. Only infants for whom a sample 39 was available at both D0 and D28 were included in the analysis resulting in combined analysis of a maximum of 98 samples from 49 cases and 258
samples from 129 controls (actual numbers in analysis vary per availability of assay data and are listed in Table 1 , Figure 1 ).
Cell culture
PBMC were retrieved from liquid nitrogen storage, thawed and rested for 2 were scanned using an Illumina iScan machine and data extracted using Genome Studio software.
Ex vivo IFN-γ ELISpot assay
The ex vivo IFN-γ ELISpot assay was performed as previously described using a human IFN-γ ELISpot kit (capture mAb -D1K) (Mabtech) 8 . of Illumina HumanHT 12 V4 microarrays were imported into R using beadarray 64 . Probes were background corrected using negative control probes followed by quantile normalization using the neqc command 65 A linear model was fitted using limma 66 to determine differential expression adjusted for vaccine, day, stimulus, gender, age, ethnicity and batch effects.
Array quality weights were incorporated 67 to account for between array quality differences. To account for between patient correlations, the duplicateCorrelation command from the limma package was used. Nominal pvalues were corrected for multiple hypotheses testing using the BenjaminiHochberg procedure 68 . Due to the heterogeneity of the samples, a lenient cut off at an FDR of 20% was chosen to identify genes as significantly differentially Gene set enrichment analysis was carried out using the cerno test from the tmod package in R. Modules for the enrichment analysis were taken from Li et al. 69 . Datasets used for comparative analysis to CMV infected CD8 T-cells were respectively. CMV status prediction was performed using 55 overlapping probes which were differentially expressed between CMV negative and CMV strongly positive (ELISpot >100 SFC/million) infants at an FDR of 20%. Only infants with at least two positive samples were labelled as suspected CMV+.
Data availability
Raw and normalized expression data have been deposited at Gene Expression
Omnibus under the accession number GSE98550
